Gilead Sciences, Inc. GILDannounced encouraging data from a proof-of-concept study of experimental combination therapies for patients with advanced fibrosis due to nonalcoholic steatohepatitis ("NASH"). The data were presented at The International Liver Congress 2018 in Paris.
Gilead (GILD) Presents Encouraging Data on NASH Therapies
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться